v3.26.1
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Jun. 30, 2026
Summary of Significant Accounting Policies [Abstract]  
Schedule of Fair Value of Financial Instruments

The fair value of financial instruments measured on a recurring basis is as follows:

 

    As of June 30, 2026  
Description   Total     Level 1     Level 2     Level 3  
Liabilities:                        
Warrant liability   $ 303,805     $     $     $ 303,805  
Total liabilities at fair value   $ 303,805     $     $     $ 303,805  

 

    As of September 30, 2025  
Description   Total     Level 1     Level 2     Level 3  
Liabilities:                        
Warrant liability   $ 1,266,894     $     $     $ 1,266,894  
Total liabilities at fair value   $ 1,266,894     $     $     $ 1,266,894  
Schedule of Warrant Liability Measured at Fair Value

The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis using unobservable level 3 inputs for the nine months ended June 30, 2026 and 2025, respectively.

 

    2026     2025  
Warrant liability            
Balance as of beginning of Period   $ 1,266,894     $ 2,140,315  
Change in fair value of warrant liability     (620,171 )     (1,099,421 )
Exercises     (342,918 )      
Balance as of end of period   $ 303,805     $ 1,040,894  
Schedule of Computation of Basic and Diluted Loss Per Share

The table below presents the computation of basic and diluted loss per share:

 

    Three Months Ended     Nine Months Ended  
    June 30,     June 30,  
    2026     2025     2026     2025  
Basic:                        
Net loss available to common stockholders - basic   $ (2,006,331 )   $ (1,500,868 )   $ (5,826,243 )   $ (1,986,153 )
Weighted average common shares outstanding - basic     8,661,624       8,100,603       8,511,313       6,141,509  
Loss per share - basic   $ (0.23 )   $ (0.19 )   $ (0.68 )   $ (0.32 )
                                 
Diluted:                                
Net loss available to common stockholders – diluted   $ (2,407,254 )   $ (1,500,868 )   $ (6,438,772 )   $ (1,986,153 )
Weighted average common shares outstanding - diluted     8,739,505       8,100,603       8,621,075       6,141,509  
Loss per share - diluted   $ (0.28 )   $ (0.19 )   $ (0.75 )   $ (0.32 )
Schedule of Weighted Average Common Shares

The following table presents the computation of weighted average common shares considered in the computation of diluted net loss per share during the three and nine months ended June 30,

 

    Three Months Ended     Nine Months Ended  
    June 30,     June 30,  
    2026     2025     2026     2025  
Denominator (weighted average shares)                        
Basic common shares outstanding     8,661,624       8,100,603       8,511,313       6,141,509  
Dilutive stock options                        
Dilutive restricted stock units                        
Dilutive warrants     77,881             109,762        
Diluted common shares outstanding     8,739,505       8,100,603       8,621,075       6,141,509  
Schedule of Basic Net Loss Per Share as their Effect Would have Been Anti-Dilutive

The following potential common shares were not considered in the computation of basic net loss per share as their effect would have been anti-dilutive for the three and nine months ended June 30, 2026 and 2025:

 

    Three Months Ended     Nine Months Ended  
    June 30,     June 30,  
    2026     2025     2026     2025  
Warrants     283,230       1,174,322       251,349       1,174,322  
Stock options     1,127,065       1,021,952       1,127,065       1,021,952  
Restricted stock units     105,390       141,421       105,390       141,421